Gilboa Therapeutics vs Infinimmune
Gilboa Therapeutics vs Infinimmune, compared side by side on 14 data points: what each one does, how big it is, what it has raised, the tech running each site, and what users report. We score both out of 100 on traction, team and visibility: Gilboa Therapeutics is on 43/100 and Infinimmune on 60/100.
Where each one leads
Gilboa Therapeutics
Leads on none of the measures we hold for both companies.
Infinimmune
- our overall score: 60/100 against 43/100
- agent readiness: 42/100 against 22/100
- domain rating: 20/100 against 4/100
- headcount: 22 against 2
- LinkedIn following: 4,055 against 956
At a glance
| Measure | Gilboa Therapeutics | Infinimmune |
|---|---|---|
| What it is | Preclinical biopharma developing next-gen cancer immunotherapies using proprietary SolidT technology. | Developing human-derived antibodies for inflammatory diseases and cancer using AI and proprietary platforms. |
| Category | Biopharmaceuticals, Immunotherapy, Cancer Treatment, Biotechnology | Biotechnology, Pharmaceuticals, Artificial Intelligence, HealthTech |
| Sells toBusiness model | B2G | B2B |
| Offering | Hardware | Platform |
| Founded | 2017 | 2017 |
| Headquarters | Tel Aviv, Israel | Alameda, United States |
| Status | Inactive | Active |
Size, funding and growth
| Measure | Gilboa Therapeutics | Infinimmune |
|---|---|---|
| Employees | 2 | 22 |
| Headcount growthLast 12 months | -49.5% | Not published |
| Total funding | Not published | $75.0M |
| Latest round | Not published | Series A |
| LinkedIn followers | 956 | 4,055 |
StartupHub scores
Our own 0-100 ratings. They measure company strength and site quality, not which product suits you.
| Measure | Gilboa Therapeutics | Infinimmune |
|---|---|---|
| StartupHub scoreOur 0-100 rating | 43/100 | 60/100 |
| Traction | 11/100 | 53/100 |
| Team | Not published | 70/100 |
| Search visibility | 54/100 | 23/100 |
| Quality | Not published | 68/100 |
| Agent readinessHow well an AI agent can read and act on the site | F (22/100) | D (42/100) |
| Domain ratingLink authority, 0-100 | 4/100 | 20/100 |
Technology
Detected on each public site, so it reflects the marketing stack as well as the product.
| Measure | Gilboa Therapeutics | Infinimmune |
|---|---|---|
| CDN | Not detected | Cloudflare |
| CMS | Not detected | Webflow |
| Analytics | Not detected | Google Analytics 4 |
Gilboa Therapeutics vs Infinimmune: common questions
Which is better, Gilboa Therapeutics or Infinimmune?
On our 0-100 score Infinimmune rates higher (60/100 against 43/100). The score weights traction, team, visibility and profile completeness, so it reflects company strength rather than which product suits you. We compare the two on 14 data points above: read the rows that match what you are buying for.
How do Gilboa Therapeutics and Infinimmune compare on the numbers?
Infinimmune leads on our overall score (60/100 against 43/100), agent readiness (42/100 against 22/100), domain rating (20/100 against 4/100), headcount (22 against 2), LinkedIn following (4,055 against 956).
Read the full Gilboa Therapeutics review and pricing or the Infinimmune review and pricing. You can also browse other Gilboa Therapeutics alternatives we track.